RAS buzz lifts Erasca
But the company still has a lot to prove with ERAS-0015.
BridgeBio Oncology shows early promise
The group’s on/off KRAS G12C inhibitor looks good, though patient numbers are small.
FDA red and green lights: December 2025
Seven oncology approvals included nods for subcutaneous Rybrevant and Lunsumio.
Syndax switches first-line plans
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
Henlius and Ottimo join the bispecific bundle
Two new PD-(L)1 x VEGF projects have entered the clinic.
BeOne starts another front-line sonrotoclax fight
The new phase 3 trial, in first-line CLL, is expected to begin in January 2026.
SABCS 2025 – Carrick sees a way forward in CDK7
The group will start a pivotal trial of samuraciclib following promising second-line results.
